A VEGF-A/SOX2/SRSF2 network controls VEGFR1 pre-mRNA alternative splicing in lung carcinoma cells

DOI PDF Web Site 1 Citations

Description

<jats:title>Abstract</jats:title><jats:p>The splice variant <jats:italic>sVEGFR1-i13</jats:italic> is a truncated version of the cell membrane-spanning VEGFR1 receptor that is devoid of its transmembrane and tyrosine kinase domains. We recently showed the contribution of sVEGFR1-i13 to the progression and the response of squamous lung carcinoma to anti-angiogenic therapies. In this study, we identify VEGF165, a splice variant of VEGF-A, as a regulator of sVEGFR1-i13 expression in these tumors, and further show that VEGF<jats:sub>165</jats:sub> cooperates with the transcription factor SOX2 and the splicing factor SRSF2 to control sVEGFR1-i13 expression. We also demonstrate that anti-angiogenic therapies up-regulate sVEGFR1-i13 protein level in squamous lung carcinoma cells by a mechanism involving the VEGF<jats:sub>165</jats:sub>/SOX2/SRSF2 network. Collectively, our results identify for the first time a signaling network that controls <jats:italic>VEGFR1</jats:italic> pre-mRNA alternative splicing in cancer cells.</jats:p>

Journal

  • Scientific Reports

    Scientific Reports 9 (1), 2019-01-23

    Springer Science and Business Media LLC

Citations (1)*help

See more

Report a problem

Back to top